Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD 1) in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by assessing overall response rates (ORRs) per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 The study will also evaluate the safety and tolerability profile of the 3 combinations

Study Overview

• Status: Completed
• Conditions: Solid Tumor; Metastatic Cancer
• Intervention / Treatment: Drug: Sym021; Drug: Sym022; Drug: Sym023; Drug: Irinotecan Hydrochloride

Detailed Description

The study will evaluate safety and efficacy in patients with:

• Biliary tract carcinomas patients who have progressed on one prior line of gemcitabine and platinum-based chemotherapy in the metastatic setting.
• Esophageal squamous cell carcinoma patients who have progressed on one prior line of platinum-based chemotherapy in the metastatic setting.

The trial is set up as 3 sub-studies.

• Sub-study 1 includes biliary tract carcinoma patients and is composed of 2 investigational combination treatment arms (Sym021+Sym022 [Arm A] and Sym021+Sym023 [Arm B]).
• Sub-study 2, includes biliary tract carcinoma patients and is composed of one investigational combination treatment arm:Sym021+Sym023+irinotecan. A safety lead- in phase is included to assess tolerability of the combination. A Study Safety Team will review clinical and laboratory safety data and will make decisions regarding the continued enrollment after the safety lead-in phase.
• Sub-Study 3, includes esophageal squamous cell carcinoma patients and is composed of one investigational combination treatment arm: Sym021+Sym023+irinotecan. Dose of irinotecan in this arm will be selected based upon the safety lead in in sub-study 2 period.

August 2021 : Based upon results from a recent per protocol Interim Analysis (IA) it is has been decided as of 3rd of August 2021 to stop further enrollment into Sub-study 1 Arm A (Sym021+Sym022). Future patients will be allocated to either Sub-study 1 Arm B (Sym021+Sym023) or Sub-study 2 (Sym021+Sym023+irinotecan).

• Study Type: Interventional
• Enrollment (Actual): 78
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 1X5
      • Princess Margaret Cancer Centre
• France
  • Dijon, France, 21000
    • Centre Georges-François Leclerc, Department of Medical Oncology
  • Saint-Herblain, France, 44805
    • Institut de Cancérologie de l'Ouest
• Spain
  • Barcelona, Spain, 08035
    • Vall d'Hebron Institute of Oncology
  • Madrid, Spain, 28040
    • Hospital Universitario San Carlos
• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic - Jacksonville
    • Tampa, Florida, United States, 33612
      • Moffitt Cancer Center
  • Illinois
    • Chicago, Illinois, United States, 60637-1470
      • University of Chicago
  • Kansas
    • Westwood, Kansas, United States, 66205
      • University of Kansas Medical Center (KUMC)
  • Michigan
    • Grand Rapids, Michigan, United States, 49546
      • START Midwest
  • Minnesota
    • Rochester, Minnesota, United States, 55902
      • Mayo Clinic
  • New York
    • Bronx, New York, United States, 10461
      • Montefiore Medical Center Prime
    • New York, New York, United States, 10029
      • Mount Sinai - PRIME
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • University of Cincinnati Medical Center
  • Texas
    • Houston, Texas, United States, 77230
      • MD Anderson
  • Virginia
    • Fairfax, Virginia, United States, 22031
      • Virginia Cancer Specialists, PC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

For Sub-study 1 and 2:

• Patients with locally advanced or metastatic biliary tract carcinoma including adenocarcinoma of the intra- and/or extra-hepatic bile ducts and gallbladder carcinoma. Patients with ampullary cancers are excluded.
• Patients must only have received and progressed on or be intolerant of first-line gemcitabine and platinum-based chemotherapy in metastatic/advanced setting and should not have received prior anti-PD-(L)1 therapy. Patients with known fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, or isocitrate dehydrogenase 1 (IDH1) mutation will be excluded. Prior anti-PD-(L)1 therapy may be allowed during the trial if regulatory approval for such therapy is obtained while this trial is enrolling.

For Sub-study 3:

• Patients with with locally advanced or metastatic esophageal squamous cell carcinoma
• Patients must only have received and progressed on or be intolerant of first-line platinum-based chemotherapy in metastatic/advanced setting and should have received prior anti-PD-(L)1 therapy. Patients with mixed adenosquamous histology cancers are excluded.

For all Sub-studies :

• Patients with measurable disease according to RECIST v1.1
• Patients with an ECOG PS of 0 or 1, and anticipated life expectancy of ≥3 months
• Patients must have adequate organ function as indicated by laboratory values
• Adequate contraception required as appropriate

Exclusion Criteria:

• Patients with central nervous system (CNS) malignancy, untreated or unstable metastases
• Patients with significant cardiovascular disease

• Patients with

  1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to the first study drug dose
  2. Active uncontrolled bleeding or a known bleeding diathesis
• Patients with a significant pulmonary disease or condition
• Patients with a current or recent (within 6 months) significant gastrointestinal disease or condition
• Patients with Gilbert's syndrome or patients with UGT1A1*28 homozygosity (also known as UGT1A1 7/7 genotype)
• Patients with a significant ocular disease or condition
• Patients with an active, known or suspected autoimmune disease
• Patients with any other serious/active/uncontrolled infection
• Patients with a history of organ transplantation
• Patients with human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active infection with hepatitis B virus or hepatitis C virus
• Prior therapy with irinotecan
• For Sub-study 1 and Sub-study 2: Anti-PD-(L)1, anti -LAG-3* or anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other immuno-oncology (IO) therapies.
• For Sub-study 3: Anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other IO therapies (other than anti-PD-(L)1 agents).
• Patients must not be on warfarin, if they have a history of acute immune-related thrombocytopenia; patients must not be on strong cytochrome P450 (CYP) 3A4 inducers, strong CYP3A4 inhibitors, or strong UGT1A1 inhibitors.
• Patients with a known or suspected hypersensitivity to any of the excipients of formulated study drug
• Patients with unresolved >Grade 1 toxicity associated with any prior antineoplastic therapy
• Sub-study 1 and Sub-study 2: Patients with known FGFR2 fusion or rearrangement, or IDH1 mutation.
• For Sub-study 3: Patients with a history of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sym021+Sym022 [ARM A] for BTC patients; Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.	Drug: Sym021; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-PD-1; Drug: Sym022; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-LAG-3
Experimental: Sym021+Sym023 [ARM B] for BTC patients; Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.	Drug: Sym021; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-PD-1; Drug: Sym023; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-TIM-3
Experimental: Sym021+Sym023+irrinotecan for BTC patients; Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.	Drug: Sym021; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-PD-1; Drug: Sym023; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-TIM-3; Drug: Irinotecan Hydrochloride; IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Experimental: Sym021+Sym023+irrinotecan for ESCC patients; Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.	Drug: Sym021; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-PD-1; Drug: Sym023; IV infusion over 30 minutes on day 1 and 15 of each cycle.; Other Names: Anti-TIM-3; Drug: Irinotecan Hydrochloride; IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the preliminary efficacy of the combinations Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan in patients with BTC or ESCC by assessing overall response rates (ORRs) per Investigator assessment using RECISTv.1.1	Objective Response Rate (ORR) per Investigator assessment of antitumor activity (based on radiological evidence per RECIST v1.1)	Until disease progression or end of study, whichever comes first, assessed up to 24 months
To evaluate the incidence, severity, and relationship of (S)AEs collected from administration of the first dose of study drug until 30 days after the last dose of the 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irrinotecan)	Calculation of AE incidence will be based on the number of patients per AE category; AEs in total and sorted by frequency, AEs by relationship, SAEs in total and by relationship, Immune mediated AEs, Fatal AEs	Through study completion up to 30 days after last dose of the three combinations
To evaluate the AEs leading to dose interruption, dose delays, and permanent treatment stop of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023 +irinotecan)	Calculation of AE incidence will be based on the number of patients per AE category ; AEs leading to dose interruption, dose delays, and permanent treatment stop	Through study completion up to a maximum of 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak plasma (irinotecan) and serum( mAbs) Concentration (Cmax) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+irinotecan)	Peak serum concentration (Cmax) for each mAbs in each combination.	First study dose and throughout the trial, up to 2 years
Area under the serum concentration versus time curve (AUC) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+ irinotecan)	Area under the serum concentration versus time curve (AUC) for each mAbs in each combination.	First dose of study drug and throughout the trial, up to 2 years
Time to reach maximum concentration (Tmax) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+irinotecan)	Time to reach maximum concentration (Tmax) for each mAbs in each combination.	First dose of study drug and throughout the trial, up to 2 years
Trough concentration (Ctrough) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023 + irinotecan)	Trough concentration (Ctrough) for each mAbs in each combination.	First dose of study drug and throughout the trial, up to 2 years
Plasma concentration for irinotecan and its metabolite in the combination Sym021+Sym023+ Irinotecan	Plasma concentration at the end of infusion for irinotecan and its metabolite in the combination Sym021+Sym023+ Irinotecan	First dose of study drug and throughout the trial, up to 2 years
To confirm the RP2D of each combination	Confirmation of the RP2D, based on the dose-response relationship (in case more than one dose level is implemented), overall tolerability and safety profile, and the PK and pharmacodynamic data	36 month
Evaluation of Duration of Response (DOR)	Duration of the OR will be determined from the day initial response is observed to day of progression is observed. Number and percentages of patients with documented OR will be presented.	Until disease progression or end of study, whichever comes first, assessed up to 24 months
Evaluation of Progression-Free Survival (PFS)	Will be calculated as from the first study drug dose to the day progression of disease is confirmed radiological or date of death.	From first study drug dose until disease progression or end of study, whichever comes first, assessed up to 24 months
Evaluation of Disease Control Rate (DCR), defined as CR, PR, or stable disease (SD) ≥6 months	Will be calculated according to standard response criteria	Until disease progression or end of study, whichever comes first, assessed up to 6 months
Evaluation of duration of response.	Will be calculated from the day the initial response is observed to the day progression of disease is observed	Until disease progression or end of study, whichever comes first, assessed up to 24 months
Evaluation of Objective Response Rate (ORR) per Investigator assessment (based on Immunotherapeutics Response Evaluation Criteria in Solid Tumors [iRECIST])	Will be based on Investigators assessment on Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST)	Until disease progression or end of study, whichever comes first, assessed up to 24 months
Evaluation Overall Survival (OS)	Overall survival will be derived from start of treatment until death or latest survival follow-up.	From first dose of study drug until death or latest survival follow-up assessed up to 30 month
Evaluation of immunogenicity of each antibody drug in the combinations	Occurrence of antidrug antibody (ADA) measured in serum at selected time points during the study	From screening up to 30 months

Collaborators and Investigators

• Sponsor: Symphogen A/S
• Investigators: Principal Investigator: Nehal Lakhani, MD, START Midwest

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2020
• Primary Completion (Actual): June 3, 2024
• Study Completion (Actual): June 3, 2024

Study Registration Dates

• First Submitted: October 29, 2020
• First Submitted That Met QC Criteria: November 17, 2020
• First Posted (Actual): November 24, 2020

Study Record Updates

• Last Update Posted (Actual): June 26, 2024
• Last Update Submitted That Met QC Criteria: June 25, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Keywords: Anti-PD-1; PD-1; TIM-3; Irinotecan; Cholangiocarcinoma; PD1; Locally advanced/unresectable; Metastatic solid tumor; Anti-TIM-3; TIM3; CCA; Biliary Tract Carcinomas; Gallbladder; Esophageal Squamous Cell Carcinoma; ESCC
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplastic Processes; Neoplasms; Neoplasm Metastasis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase Inhibitors; Topoisomerase I Inhibitors; Irinotecan
• Other Study ID Numbers: Sym021-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No